Pulmonary Disease Specific Data Models
Informing respiratory study assumptions with pulmonary research data
KerusCloud® simulations are very intuitive. You can have a quick understanding of what the goals are, what the outputs could be, and it enables quick decision-making from the whole team regardless of their statistical background.
De-risk Respiratory Clinical Trials with Pulmonary Data Models
KerusCloud® Pulmonary Suite equips your team with expertly curated clinical trial data models across a wide range of respiratory conditions—from COPD and IPF to asthma and RSV. Designed by our Data Science team using real-world, regulatory-grade datasets, the suite helps sponsors and researchers identify optimal endpoints, biomarkers, patient populations, and design strategies. Whether you’re optimizing a Phase II study or validating assumptions for regulatory submission, KerusCloud® accelerates decision-making and reduces trial risk—before your study ever begins.
The pulmonary suite provides reliable, ready-to-use historical data across a range of pulmonary indications (Figure 1). Offered at different complexity levels according to project demands, the data models give an extensive overview of the pulmonary clinical trial landscape, clinical outcomes, and patient characteristics. This information can then inform study simulations in KerusCloud® to support evidence-based clinical trial design.
Data Science Services can sift through information relating to thousands of clinical trials in the suite, identifying relevant historical data to inform the planning of your study. The suite can be searched by:
- Disease
- Endpoint
- Patient population
- Biomarker
- Interventions
- Phase
- Enrolment
- Design
Selected information can be built into realistic synthetic patient-level datasets for use in running virtual clinical trials in KerusCloud®. Trial scenarios of interest can be simulated, and their outcomes examined to answer key ‘what if’ questions relating to study design and analysis. This ensures you identify, with confidence, the right approach for your pulmonary asset in a real clinical trial.
Pulmonary Suite
Complexity Level Overview
Figure 1. Disease models included in the Pulmonary Suite are available at four levels of complexity/granularity: 1) landscape overview, 2) standardized endpoint, 3) standardized data and 4) comprehensive data model. The indications included are pulmonary artery hypertension (PAH), idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), asthma, COVID-19 (CV19), bronchiectasis (B), influenza (Flu), non-small cell lung cancer (NSCLC), rhinovirus (hRV) and respiratory syncytial virus (RSV).
Suggested For You
news
June 19th, 2025
MMS Wins in the 2025 Fierce CRO Awards for Excellence in Client Service and Partnership and Dr. Uma Sharma Named CRO Champion
perspectives
June 17th, 2025
Solving Data Complexity with Real-Time Insights, Predictive AI, and Smarter Decision-Making with Datacise
regulatory intelligence
June 16th, 2025
Key MedDRA Coding Gaps Highlighted at the ISCTM 2025 Scientific Meeting
perspectives
June 10th, 2025
Applying Artificial Intelligence (AI) and Real-World Evidence to Boost Efficiency in Patient Safety Narratives
perspectives
June 3rd, 2025
Choosing the Right Strategy: Parallel, Sequential, and Staggered Regulatory Submissions
news
May 28th, 2025
MMS Named Finalist for Fierce CRO Award in Excellence in Client Service and Partnership, CEO shortlisted for the CRO Champion Award
perspectives
May 28th, 2025
A Season of Change: Why the REMS Industry Consortium Matters More Than Ever
perspectives
May 20th, 2025
Navigating FDA OMOR Meetings: A Comprehensive Guide to Type X, Y, and Z Meetings for OTC Drug Sponsors
perspectives
May 6th, 2025
Why Clinical Trial Simulation Is Reshaping Drug Development: A Q&A with Dr. Aiden Flynn
perspectives
April 24th, 2025
How to Derisk Clinical Development with Unified Trial Design and Regulatory Strategy
perspectives
April 8th, 2025
Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements
news
April 3rd, 2025
Datacise by MMS Wins 2025 Data Breakthrough Award for Best Data Science Solution